Thalidomide for previously untreated indolent or smoldering multiple myeloma (Q33146651)

22 July 2017

Thalidomide for previously untreated indolent or smoldering multiple myeloma (English)

1 reference

22 July 2017

0 references

1 reference

9

Gertz MA

1 reference

22 July 2017

6

Lust JA

1 reference

22 July 2017

4

Lacy MQ

1 reference

22 July 2017

2

Dispenzieri A

1 reference

22 July 2017

Rajkumar SV

1

1 reference

22 July 2017

Fonseca R

3

1 reference

22 July 2017

Geyer S

5

1 reference

22 July 2017

Kyle RA

7

1 reference

22 July 2017

Greipp PR

8

1 reference

22 July 2017

Witzig TE

10

1 reference

22 July 2017

1 August 2001

1 reference

22 July 2017

1 reference

22 July 2017

15

1 reference

22 July 2017

8

1 reference

22 July 2017

1274-1276

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402183

22 July 2017

0 references

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

1 reference

7 January 2021

Smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

Bone marrow angiogenesis and progression in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402183

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402183

1 reference

Dimensions Publication ID

22 July 2017

0 references

1 reference